TaiMed Biologics (4147) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.029x

Based on the latest financial reports, TaiMed Biologics (4147) has a cash flow conversion efficiency ratio of 0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$115.29 Million ≈ $3.63 Million USD) by net assets (NT$3.92 Billion ≈ $123.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

TaiMed Biologics - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how TaiMed Biologics's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 4147 total liabilities for a breakdown of total debt and financial obligations.

TaiMed Biologics Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TaiMed Biologics ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Angel Oak Financial Strategies Income Term Trust NYSE:FINS	0.033x
Yunnan luoping Zinc & Electricity Co Ltd SHE:002114	0.044x
Beijing Hanbang Technology Corp SHE:300449	-0.118x
Antofagasta PLC LSE:ANTO	0.043x
Climb Bio Inc NASDAQ:CLYM	-0.097x
Cable One Inc NYSE:CABO	0.102x
Meihua International Medical Technologies Co Ltd NASDAQ:MHUA	-0.120x
J.Kumar Infraprojects Limited NSE:JKIL	0.129x

Annual Cash Flow Conversion Efficiency for TaiMed Biologics (2015–2024)

The table below shows the annual cash flow conversion efficiency of TaiMed Biologics from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see 4147 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$4.02 Billion ≈ $126.74 Million	NT$-379.55 Million ≈ $-11.96 Million	-0.094x	-845.68%
2023-12-31	NT$2.57 Billion ≈ $80.85 Million	NT$-25.60 Million ≈ $-806.57K	-0.010x	+95.52%
2022-12-31	NT$2.71 Billion ≈ $85.53 Million	NT$-605.21 Million ≈ $-19.07 Million	-0.223x	-210.36%
2021-12-31	NT$2.94 Billion ≈ $92.67 Million	NT$-211.28 Million ≈ $-6.66 Million	-0.072x	-21.50%
2020-12-31	NT$3.42 Billion ≈ $107.62 Million	NT$-201.94 Million ≈ $-6.36 Million	-0.059x	+67.65%
2019-12-31	NT$3.59 Billion ≈ $112.99 Million	NT$-655.31 Million ≈ $-20.65 Million	-0.183x	-42.60%
2018-12-31	NT$4.08 Billion ≈ $128.56 Million	NT$-522.86 Million ≈ $-16.47 Million	-0.128x	-6.49%
2017-12-31	NT$4.29 Billion ≈ $135.23 Million	NT$-516.48 Million ≈ $-16.27 Million	-0.120x	-229.21%
2016-12-31	NT$4.71 Billion ≈ $148.51 Million	NT$-172.29 Million ≈ $-5.43 Million	-0.037x	+59.87%
2015-12-31	NT$4.90 Billion ≈ $154.37 Million	NT$-446.26 Million ≈ $-14.06 Million	-0.091x	--

About TaiMed Biologics

TWO:4147 Taiwan Biotechnology

Market Cap

$425.63 Million

NT$13.51 Billion TWD

Market Cap Rank

#13375 Global

#502 in Taiwan

Share Price

NT$49.45

Change (1 day)

+0.10%

52-Week Range

NT$48.05 - NT$95.60

All Time High

NT$341.00